Notice of Closed Meeting, 6177-6178 [2018-02825]
Download as PDF
Federal Register / Vol. 83, No. 30 / Tuesday, February 13, 2018 / Notices
the Director, Management Analysis and
Services Office, CDC, pursuant to Public
Law 92–463. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease, Disability,
and Injury Prevention and Control Special
Emphasis Panel (SEP); Funding Opportunity
Announcement (FOA), IP18–001, Reducing
Disparities in Vaccination Coverage by
Poverty Status Among Young Children and
IP18–003, Understanding and Addressing the
Disparity in Vaccination Coverage Among
U.S. Adolescents Living in Rural versus
Urban Areas.
Dates: March 20, 2018 and March 21, 2018.
Time: 10:00 a.m.–5:00 p.m. (EDT)
Place: Teleconference, Centers for Disease
Control and Prevention, Room 1080, 8
Corporate, Atlanta, GA 30329.
Agenda: To review and evaluate grant
applications.
For Further Information Contact: Gregory
Anderson, M.S., M.P.H., Scientific Review
Officer, CDC, 1600 Clifton Road NE, Mailstop
E–60, Atlanta, Georgia 30333, (404) 718–
8833, gca5@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register Notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2018–02826 Filed 2–12–18; 8:45 am]
BILLING CODE 4163–18–P
Exposure and Prevention Advisory
Committee shall, at a minimum: (1)
Review the Federal programs and
services available to individuals and
communities exposed to lead; (2) review
current research on lead exposure to
identify additional research needs; (3)
review and identify best practices, or
the need for best practices regarding
lead screening and the prevention of
lead poisoning; (4) identify effective
services, including services relating to
healthcare, education, and nutrition for
individuals and communities affected
by lead exposure and lead poisoning,
including in consultation with, as
appropriate, the lead exposure registry
as established in Section 2203(b) of
Public Law 114–322; and (5) undertake
any other review or activities that the
Secretary determines to be appropriate.
This advisory committee will review
research and Federal programs and
services related to lead poisoning and to
identify effective services and best
practices for addressing and preventing
lead exposures in communities.
FOR FURTHER INFORMATION CONTACT:
Perri Ruckart, M.P.H., Epidemiologist,
CDC, 4770 Buford Highway NE, Atlanta,
Georgia 30341, telephone (770) 488–
3808; afp4@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2018–02823 Filed 2–12–18; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Lead Exposure and Prevention
Advisory Committee (LEPAC); Notice
of Establishment
Centers for Disease Control and
Prevention
ACTION:
Notice of charter establishment.
Pursuant to the Section 2203
of Public Law 114–322 (Water
Infrastructure Improvements for the
Nation Act)(Registry for Lead Exposure
and Advisory Committee), and the
Federal Advisory Committee Act of
October 6, 1972, the Director, Centers
for Disease Control and Prevention
(CDC), announces the establishment of
the Lead Exposure and Prevention
Advisory Committee. The Lead
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
23:12 Feb 12, 2018
Jkt 244001
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Management Analysis and
Services Office, CDC, pursuant to Public
Law 92–463. The grant applications and
PO 00000
Frm 00019
Fmt 4703
Sfmt 4703
6177
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease, Disability,
and Injury Prevention and Control Special
Emphasis Panel; (SEP) DP18–001, Etiology
and Outcome of Inflammatory Bowel Disease.
Date: April 11, 2018.
Time: 11:00 a.m.–6:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact: Jaya
Raman Ph.D., Scientific Review Officer, CDC,
4770 Buford Highway, Mailstop F80, Atlanta,
Georgia 30341, Telephone: (770) 488–6511,
kva5@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2018–02829 Filed 2–12–18; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Management Analysis and
Services Office, CDC, pursuant to Public
Law 92–463. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease, Disability,
and Injury Prevention and Control Special
Emphasis Panel (SEP); DD18–001, Birth
Defects Study To Evaluate Pregnancy
exposureS (BD–STEPS) II.
E:\FR\FM\13FEN1.SGM
13FEN1
6178
Federal Register / Vol. 83, No. 30 / Tuesday, February 13, 2018 / Notices
Date: April 18, 2018.
Time: 10:00 a.m.–6:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact: Jaya
Raman, Ph.D., Scientific Review Officer,
CDC, 4770 Buford Highway, Mailstop F80,
Atlanta, Georgia 30341, Telephone: (770)
488–6511, kva5@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2018–02825 Filed 2–12–18; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Solicitation of Nominations for
Appointment to the Advisory
Committee on Breast Cancer in Young
Women (ACBCYW)
ACTION:
Notice.
The Centers for Disease
Control and Prevention (CDC) is seeking
nominations for membership on the
ACBCYW. The ACBCYW consists of 15
experts in fields associated with breast
cancer, disease prevention, early
detection, diagnosis, public health,
social marketing, genetic screening and
counseling, treatment, rehabilitation,
palliative care, and survivorship in
young women, or in related disciplines
with a specific focus on young women.
Nominations are being sought for
individuals who have expertise and
qualifications necessary to contribute to
the accomplishments of the committee’s
objectives. Nominees will be selected
based on expertise in the fields of breast
health, breast cancer, disease prevention
and risk reduction, survivorship
(including metastatic breast cancer),
hereditary breast and ovarian cancer
(HBOC), or in related disciplines with a
specific focus on young women. Persons
with personal experience with early
onset breast cancer are also eligible to
apply. This includes, but may not be
limited to breast cancer survivors <45
years of age and caregivers of said
persons. Federal employees will not be
considered for membership. Members
may be invited to serve up to four-year
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
23:12 Feb 12, 2018
Jkt 244001
terms. Selection of members is based on
candidates’ qualifications to contribute
to the accomplishment of ACBCYW
objectives (https://www.cdc.gov/maso/
facm/facmacbcyw.html).
DATES: Nominations for membership on
the ACBCYW must be received no later
than March 26, 2018. Packages received
after this time will not be considered for
the current membership cycle.
ADDRESSES: All nominations should be
mailed to Temeika L. Fairley, Ph.D.
c/o ACBCYW Secretariat, Centers for
Disease Control and Prevention, 3719
North Peachtree Road, Building 100
Chamblee, Georgia 30341, or emailed
(recommended) to acbcyw@cdc.gov.
FOR FURTHER INFORMATION CONTACT:
Temeika L. Fairley, Ph.D., Designated
Federal Officer, National Center for
Chronic Disease Prevention and Health
Promotion, CDC, 4770 Buford Highway
NE, Mailstop F–76, Atlanta, Georgia
30341; 770–488–4518; acbcyw@cdc.gov.
SUPPLEMENTARY INFORMATION: The U.S.
Department of Health and Human
Services policy stipulates that
committee membership be balanced in
terms of points of view represented, and
the committee’s function. Appointments
shall be made without discrimination
on the basis of age, race, ethnicity,
gender, sexual orientation, gender
identity, HIV status, disability, and
cultural, religious, or socioeconomic
status. Nominees must be U.S. citizens,
and cannot be full-time employees of
the U.S. Government. Current
participation on federal workgroups or
prior experience serving on a federal
advisory committee does not disqualify
a candidate; however, HHS policy is to
avoid excessive individual service on
advisory committees and multiple
committee memberships. Committee
members are Special Government
Employees, requiring the filing of
financial disclosure reports at the
beginning and annually during their
terms. CDC reviews potential candidates
for ACBCYW membership each year,
and provides a slate of nominees for
consideration to the Secretary of HHS
for final selection. HHS notifies selected
candidates of their appointment near
the start of the term in December 2018,
or as soon as the HHS selection process
is completed. Note that the need for
different expertise varies from year to
year and a candidate who is not selected
in one year may be reconsidered in a
subsequent year.
Nominees must be U.S. citizens, and
cannot be full-time employees of the
U.S. Government. Candidates should
submit the following items:
D Current curriculum vitae, including
complete contact information
PO 00000
Frm 00020
Fmt 4703
Sfmt 4703
(telephone numbers, mailing address,
email address);
D At least one letter of
recommendation from person(s) not
employed by the U.S. Department of
Health and Human Services.
(Candidates may submit letter(s) from
current HHS employees if they wish,
but at least one letter must be submitted
by a person not employed by an HHS
agency (e.g., CDC, NIH, FDA, etc.).
Nominations may be submitted by the
candidate him- or herself, or by the
person/organization recommending the
candidate.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both CDC and
the Agency for Toxic Substances and
Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2018–02827 Filed 2–12–18; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of closed meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Management Analysis and
Services Office, CDC, pursuant to Public
Law 92–463. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease, Disability,
and Injury Prevention and Control Special
Emphasis Panel (SEP) Funding Opportunity
Announcement (FOA), PAR 16–098,
Cooperative Research Agreements to the
World Trade Center Health Program (U01).
Dates: April 11, 2018 and April 12, 2018.
Times: 8:00 a.m.–5:00 p.m., EDT, April 11,
2018 and 8:00 a.m.–2:00 p.m. EDT, April 12,
2017.
E:\FR\FM\13FEN1.SGM
13FEN1
Agencies
[Federal Register Volume 83, Number 30 (Tuesday, February 13, 2018)]
[Notices]
[Pages 6177-6178]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-02825]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Director, Management
Analysis and Services Office, CDC, pursuant to Public Law 92-463. The
grant applications and the discussions could disclose confidential
trade secrets or commercial property such as patentable material, and
personal information concerning individuals associated with the grant
applications, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention
and Control Special Emphasis Panel (SEP); DD18-001, Birth Defects
Study To Evaluate Pregnancy exposureS (BD-STEPS) II.
[[Page 6178]]
Date: April 18, 2018.
Time: 10:00 a.m.-6:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant applications.
For Further Information Contact: Jaya Raman, Ph.D., Scientific
Review Officer, CDC, 4770 Buford Highway, Mailstop F80, Atlanta,
Georgia 30341, Telephone: (770) 488-6511, [email protected].
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention
and the Agency for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2018-02825 Filed 2-12-18; 8:45 am]
BILLING CODE 4163-18-P